State of high-grade glioma care in Africa: insights from a scoping review of the available published literature
Résumé
Background: High-grade gliomas (HGGs), WHO grade 3-4 diffuse gliomas, are aggressive primary brain tumors. Evidence on their management and outcomes in Africa remains limited, unevenly distributed, and lacking population-based incidence data. This review mapped published literature on HGG epidemiology, clinical presentation, diagnosis, treatment, and outcomes across represented African countries. Methods: This review followed the Arksey and O'Malley framework, refined by Levac et al. and the Joanna Briggs Institute, and reported per PRISMA-ScR guidelines, with the protocol prospectively registered on OSF (osf.io/hkf6g). Six databases were searched (inception-January 2026) for studies of African patients with confirmed WHO grade 3-4 gliomas; quality was appraised by two reviewers using JBI tools. Data were synthesized descriptively and stratified by study design, with no meta-analytic pooling. Results: Twenty-five studies (2008-2025) reporting 1,212 patients from 11 of 54 African countries were included; 312 (25.7%) were excluded as non-HGG or unconfirmed, leaving 900 in the confirmed cohort. Most studies were retrospective (56%), concentrated in Morocco (36%), Nigeria, and Côte d'Ivoire (16% each); 20% were case reports or small series. Raised intracranial pressure, motor deficits, and seizures showed mean study-level frequencies of 62%, 61%, and 41% (in 14, 12, and 11 of 25 studies). MRI was reported in 80% of studies; advanced imaging was rarely available. Glioblastoma predominated (833/900, 92.6%), and molecular testing (IDH, MGMT) was inconsistent. Gross total resection was achieved in a minority of patients; no study reported intraoperative adjuncts (neuronavigation, fluorescence guidance). Mortality at last follow-up ranged from 16.1%-100% (upper value from a single four-patient case series). Median overall survival ranged from 11-14 months, closely approximating median follow-up (11.7 months); these figures should be interpreted as descriptive rather than statistically estimated survival. Conclusion: Within evidence from 11 of 54 African countries, HGG care shows major diagnostic and therapeutic disparities and regional inequalities; findings should not be generalized continent-wide. Investment in infrastructure, training, molecular diagnostics, funding, and regional collaboration is needed to improve outcomes, equity of care, and evidence representativeness.
Citer ce document
Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)
Accès au document
Texte intégral archivé sur SPHAERO, en accès ouvert : lisible gratuitement en ligne après connexion. Le document reste aussi disponible à sa source. Se connecter
Voir l'article sur le site de la revueLicence et provenance
Licence : CC BY
Notice moissonnée depuis OpenAlex le 21/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →